The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Jan M Orenstein - One of the best experts on this subject based on the ideXlab platform.
-
an informatics model for Tissue banks lessons learned from the cooperative prostate Cancer Tissue resource
BMC Cancer, 2006Co-Authors: Ashokkumar A Patel, Andre Kajdacsyballa, Jules J Berman, Milton W Datta, Rajiv Dhir, John R Gilbertson, Jonathan Melamed, Anil V Parwani, Rajnish Gupta, Jan M OrensteinAbstract:Background Advances in molecular biology and growing requirements from biomarker validation studies have generated a need for Tissue banks to provide quality-controlled Tissue samples with standardized clinical annotation. The NCI Cooperative Prostate Cancer Tissue Resource (CPCTR) is a distributed Tissue bank that comprises four academic centers and provides thousands of clinically annotated prostate Cancer specimens to researchers. Here we describe the CPCTR information management system architecture, common data element (CDE) development, query interfaces, data curation, and quality control.
-
the development of common data elements for a multi institute prostate Cancer Tissue bank the cooperative prostate Cancer Tissue resource cpctr experience
BMC Cancer, 2005Co-Authors: Ashokkumar A Patel, Andre Kajdacsyballa, Jules J Berman, Maarten C Bosland, Milton W Datta, Rajiv Dhir, John R Gilbertson, Jonathan Melamed, Jan M Orenstein, Michael J BecichAbstract:The Cooperative Prostate Cancer Tissue Resource (CPCTR) is a consortium of four geographically dispersed institutions that are funded by the U.S. National Cancer Institute (NCI) to provide clinically annotated prostate Cancer Tissue samples to researchers. To facilitate this effort, it was critical to arrive at agreed upon common data elements (CDEs) that could be used to collect demographic, pathologic, treatment and clinical outcome data. The CPCTR investigators convened a CDE curation subcommittee to develop and implement CDEs for the annotation of collected prostate Tissues. The draft CDEs were refined and progressively annotated to make them ISO 11179 compliant. The CDEs were implemented in the CPCTR database and tested using software query tools developed by the investigators. By collaborative consensus the CPCTR CDE subcommittee developed 145 data elements to annotate the Tissue samples collected. These included for each case: 1) demographic data, 2) clinical history, 3) pathology specimen level elements to describe the staging, grading and other characteristics of individual surgical pathology cases, 4) Tissue block level annotation critical to managing a virtual inventory of cases and facilitating case selection, and 5) clinical outcome data including treatment, recurrence and vital status. These elements have been used successfully to respond to over 60 requests by end-users for Tissue, including paraffin blocks from cases with 5 to 10 years of follow up, Tissue microarrays (TMAs), as well as frozen Tissue collected prospectively for genomic profiling and genetic studies. The CPCTR CDEs have been fully implemented in two major Tissue banks and have been shared with dozens of other Tissue banking efforts. The freely available CDEs developed by the CPCTR are robust, based on "best practices" for Tissue resources, and are ISO 11179 compliant. The process for CDE development described in this manuscript provides a framework model for other organ sites and has been used as a model for breast and melanoma Tissue banking efforts.
Ashokkumar A Patel - One of the best experts on this subject based on the ideXlab platform.
-
an informatics model for Tissue banks lessons learned from the cooperative prostate Cancer Tissue resource
BMC Cancer, 2006Co-Authors: Ashokkumar A Patel, Andre Kajdacsyballa, Jules J Berman, Milton W Datta, Rajiv Dhir, John R Gilbertson, Jonathan Melamed, Anil V Parwani, Rajnish Gupta, Jan M OrensteinAbstract:Background Advances in molecular biology and growing requirements from biomarker validation studies have generated a need for Tissue banks to provide quality-controlled Tissue samples with standardized clinical annotation. The NCI Cooperative Prostate Cancer Tissue Resource (CPCTR) is a distributed Tissue bank that comprises four academic centers and provides thousands of clinically annotated prostate Cancer specimens to researchers. Here we describe the CPCTR information management system architecture, common data element (CDE) development, query interfaces, data curation, and quality control.
-
the development of common data elements for a multi institute prostate Cancer Tissue bank the cooperative prostate Cancer Tissue resource cpctr experience
BMC Cancer, 2005Co-Authors: Ashokkumar A Patel, Andre Kajdacsyballa, Jules J Berman, Maarten C Bosland, Milton W Datta, Rajiv Dhir, John R Gilbertson, Jonathan Melamed, Jan M Orenstein, Michael J BecichAbstract:The Cooperative Prostate Cancer Tissue Resource (CPCTR) is a consortium of four geographically dispersed institutions that are funded by the U.S. National Cancer Institute (NCI) to provide clinically annotated prostate Cancer Tissue samples to researchers. To facilitate this effort, it was critical to arrive at agreed upon common data elements (CDEs) that could be used to collect demographic, pathologic, treatment and clinical outcome data. The CPCTR investigators convened a CDE curation subcommittee to develop and implement CDEs for the annotation of collected prostate Tissues. The draft CDEs were refined and progressively annotated to make them ISO 11179 compliant. The CDEs were implemented in the CPCTR database and tested using software query tools developed by the investigators. By collaborative consensus the CPCTR CDE subcommittee developed 145 data elements to annotate the Tissue samples collected. These included for each case: 1) demographic data, 2) clinical history, 3) pathology specimen level elements to describe the staging, grading and other characteristics of individual surgical pathology cases, 4) Tissue block level annotation critical to managing a virtual inventory of cases and facilitating case selection, and 5) clinical outcome data including treatment, recurrence and vital status. These elements have been used successfully to respond to over 60 requests by end-users for Tissue, including paraffin blocks from cases with 5 to 10 years of follow up, Tissue microarrays (TMAs), as well as frozen Tissue collected prospectively for genomic profiling and genetic studies. The CPCTR CDEs have been fully implemented in two major Tissue banks and have been shared with dozens of other Tissue banking efforts. The freely available CDEs developed by the CPCTR are robust, based on "best practices" for Tissue resources, and are ISO 11179 compliant. The process for CDE development described in this manuscript provides a framework model for other organ sites and has been used as a model for breast and melanoma Tissue banking efforts.
Robert M Mentzer - One of the best experts on this subject based on the ideXlab platform.
-
sex hormone receptors in non small cell lung Cancer in human beings
The Journal of Thoracic and Cardiovascular Surgery, 1994Co-Authors: Charles C Canver, Penny L Vanderveer, Christine A Dingivan, Vincent A Memoli, Robert M MentzerAbstract:Abstract To investigate whether sex hormone receptors exist in the resected non-small-cell lung Cancer in human beings and to determine a link between the pulmonary carcinogenesis and the sex receptor status of the lung Cancer Tissue, we reviewed the case histories of 64 patients who underwent resectional therapy for non-small-cell lung Cancer between 1988 and 1990 (38 men and 26 women, mean age 65 years). Mouse monoclonal immunoglobulin G antibodies were used for immunohistochemical detection of estrogen receptors and progesterone receptors in the acetone-fixed specimen. The control group consisted of normal lung Tissue from the patients with and without bronchogenic carcinoma and breast Cancer Tissue from the patients with estrogen and progesterone receptor immunoreactivity. No evidence of estrogen and progesterone receptor immunoreactivity was present in the normal lung Tissue. All but two patients had immunoreactivity (97%) for estrogen receptors in the lung Cancer Tissue ( p p > 0.05). The differences for sex and for histologic subtypes were not statistically significant. Observed actuarial survival at 3 years was 83% for all patients with estrogen receptor immunoreactivity: 94% for women and 75% for men ( p
-
sex hormone receptors in non small cell lung Cancer in human beings
Society of Surgical Oncology. Annual meeting, 1994Co-Authors: Charles C Canver, Penny L Vanderveer, Christine A Dingivan, Vincent A Memoli, Robert M MentzerAbstract:To investigate whether sex hormone receptors exist in the resected non-small-cell lung Cancer in human beings and to determine a link between the pulmonary carcinogenesis and the sex receptor status of the lung Cancer Tissue, we reviewed the case histories of 64 patients who underwent resectional therapy for non-small-cell lungs Cancer between 1988 and 1990 (38 men and 26 women, mean age 65 years). Mouse monoclonal immunoglobulin G antibodies were used for immunohistochemical detection of estrogen receptors and progesterone receptors in the acetone-fixed specimen. The control group consisted of normal lung Tissue from the patients with and without bronchogenic carcinoma and breast Cancer Tissue from the patients with estrogen and progesterone receptor immunoreactivity
Klaus Jung - One of the best experts on this subject based on the ideXlab platform.
-
sarcosine in prostate Cancer Tissue is not a differential metabolite for prostate Cancer aggressiveness and biochemical progression
The Journal of Urology, 2011Co-Authors: Florian Jentzmik, Beate Kamlage, Bianca Bethan, Carsten Stephan, Glen Kristiansen, Michael Lein, Kurt Miller, Klaus JungAbstract:Purpose: Sarcosine in prostate Cancer Tissue samples was recently reported to be increased during prostate Cancer progression to metastasis and suggested to be a key metabolite of Cancer cell invasion and aggressiveness. We reevaluated sarcosine in prostate Cancer Tissue samples as a potential indicator of tumor aggressiveness, and as a predictor of recurrence-free survival.Materials and Methods: Sarcosine in matched samples of malignant and nonmalignant Tissue from 92 patients with prostate Cancer after radical prostatectomy was measured in the framework of a global metabolite profiling study of prostate Cancer by gas chromatography/mass spectrometry. We related results to age, prostate volume, tumor stage, Gleason score, preoperative prostate specific antigen and biochemical recurrence, defined as a persistent prostate specific antigen increase of greater than 0.2 ng/ml. Nonparametric statistical tests, ROC curves and Kaplan-Meier analyses were done.Results: Median sarcosine content in Tissue was about ...
Jonathan Melamed - One of the best experts on this subject based on the ideXlab platform.
-
an informatics model for Tissue banks lessons learned from the cooperative prostate Cancer Tissue resource
BMC Cancer, 2006Co-Authors: Ashokkumar A Patel, Andre Kajdacsyballa, Jules J Berman, Milton W Datta, Rajiv Dhir, John R Gilbertson, Jonathan Melamed, Anil V Parwani, Rajnish Gupta, Jan M OrensteinAbstract:Background Advances in molecular biology and growing requirements from biomarker validation studies have generated a need for Tissue banks to provide quality-controlled Tissue samples with standardized clinical annotation. The NCI Cooperative Prostate Cancer Tissue Resource (CPCTR) is a distributed Tissue bank that comprises four academic centers and provides thousands of clinically annotated prostate Cancer specimens to researchers. Here we describe the CPCTR information management system architecture, common data element (CDE) development, query interfaces, data curation, and quality control.
-
the development of common data elements for a multi institute prostate Cancer Tissue bank the cooperative prostate Cancer Tissue resource cpctr experience
BMC Cancer, 2005Co-Authors: Ashokkumar A Patel, Andre Kajdacsyballa, Jules J Berman, Maarten C Bosland, Milton W Datta, Rajiv Dhir, John R Gilbertson, Jonathan Melamed, Jan M Orenstein, Michael J BecichAbstract:The Cooperative Prostate Cancer Tissue Resource (CPCTR) is a consortium of four geographically dispersed institutions that are funded by the U.S. National Cancer Institute (NCI) to provide clinically annotated prostate Cancer Tissue samples to researchers. To facilitate this effort, it was critical to arrive at agreed upon common data elements (CDEs) that could be used to collect demographic, pathologic, treatment and clinical outcome data. The CPCTR investigators convened a CDE curation subcommittee to develop and implement CDEs for the annotation of collected prostate Tissues. The draft CDEs were refined and progressively annotated to make them ISO 11179 compliant. The CDEs were implemented in the CPCTR database and tested using software query tools developed by the investigators. By collaborative consensus the CPCTR CDE subcommittee developed 145 data elements to annotate the Tissue samples collected. These included for each case: 1) demographic data, 2) clinical history, 3) pathology specimen level elements to describe the staging, grading and other characteristics of individual surgical pathology cases, 4) Tissue block level annotation critical to managing a virtual inventory of cases and facilitating case selection, and 5) clinical outcome data including treatment, recurrence and vital status. These elements have been used successfully to respond to over 60 requests by end-users for Tissue, including paraffin blocks from cases with 5 to 10 years of follow up, Tissue microarrays (TMAs), as well as frozen Tissue collected prospectively for genomic profiling and genetic studies. The CPCTR CDEs have been fully implemented in two major Tissue banks and have been shared with dozens of other Tissue banking efforts. The freely available CDEs developed by the CPCTR are robust, based on "best practices" for Tissue resources, and are ISO 11179 compliant. The process for CDE development described in this manuscript provides a framework model for other organ sites and has been used as a model for breast and melanoma Tissue banking efforts.
